{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:32:29Z","timestamp":1787319149790,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>HBV pregenomic RNA (pgRNA) is a circulating biomarker for covalently closed circular DNA activity in HBV-infected individuals and has been studied for treatment efficacy, disease staging, and off-therapy outcomes; however, data on the stability are scarce. Increasing HBV pgRNA assay sensitivity may improve its predictive value and provide additional insights at low viral levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Modifications to a fully automated first (v1) generation HBV pgRNA assay improved sensitivity up to 15-fold over the previous assay. Flexible sample input volumes yielded lower limits of quantitation of 10 and 22 copies\/mL for 0.6 and 0.2\u00a0mL assays, respectively. Results are standardized to secondary standards that are traceable to the WHO HBV DNA standard, and internal and external controls are included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Comparison between v1 and modified v2 assays showed increased sensitivity from 152 copies\/mL with v1 to 10 (0.6\u00a0mL) and 22 (0.2\u00a0mL) copies\/mL with v2, respectively. Quantitated v2 results were indistinguishable from v1, indicating that comparisons can be made to previous studies. Single timepoint treatment-naive blood donors or longitudinal draws from patients with chronic hepatitis B on AB-729, an investigational siRNA therapy, showed improved detection and quantifiable pgRNA with v2 compared with v1. Stability testing demonstrated excellent HBV pgRNA plasma stability after 3 freeze-thaw cycles, for at least 7 days at 25\u201337\u00a0\u00b0C and at least 30 days at 4\u00b0C, with \u22640.25 Log U\/mL decrease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HBV pgRNA v2 assays with increased sensitivity and flexible input volumes demonstrated increased detection and quantitation of low viral titer samples. Highly sensitive HBV pgRNA assays may be useful in refining predictive treatment outcomes based on this marker. HBV pgRNA was stable under multiple conditions, which increases the reliability of this marker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/hc9.0000000000000099","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T17:06:05Z","timestamp":1679072765000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Measuring hepatitis B pgRNA stability using an updated automated HBV pgRNA assay with increased sensitivity"],"prefix":"10.1097","volume":"7","author":[{"given":"Mark","family":"Anderson","sequence":"first","affiliation":[{"name":"Infectious Disease Research, Abbott Diagnostics, Abbott Park, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stec","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Abbott Diagnostics, Abbott Park, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily P.","family":"Thi","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Warminster, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Picchio","sequence":"additional","affiliation":[{"name":"Arbutus Biopharma, Warminster, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Mbanya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Universit\u00e9 de Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Cloherty","sequence":"additional","affiliation":[{"name":"Infectious Disease Research, Abbott Diagnostics, Abbott Park, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4]]},"reference":[{"key":"R2-20240826","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"R3-20240826","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/v13050757","article-title":"Early steps of hepatitis b life cycle: from capsid nuclear import to cccDNA formation","volume":"13","author":"Diogo Dias","year":"2021","journal-title":"Viruses"},{"key":"R4-20240826","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"R5-20240826","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1440-1746.2009.05985.x","article-title":"Prevention of hepatocellular carcinoma in hepatitis B virus infection","volume":"24","author":"Lim","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"R6-20240826","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"R7-20240826","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","article-title":"Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease","volume":"12","author":"Yuen","year":"2007","journal-title":"Antivir Ther"},{"key":"R8-20240826","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1436","article-title":"Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B","volume":"4","author":"Lok","year":"2020","journal-title":"Hepatol Commun"},{"key":"R9-20240826","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/infdis\/jiv397","article-title":"Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon Alfa-2a and nucleos(t)ide analogues","volume":"213","author":"Jansen","year":"2016","journal-title":"J Infect Dis"},{"key":"R10-20240826","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J Hepatol"},{"key":"R11-20240826","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12985-018-0994-7","article-title":"High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles","volume":"15","author":"Prakash","year":"2018","journal-title":"Virol J"},{"key":"R12-20240826","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11684-017-0590-z","article-title":"Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs","volume":"11","author":"Lu","year":"2017","journal-title":"Front Med"},{"key":"R13-20240826","first-page":"119","article-title":"Serum HBV RNA levels predict significant liver fibrosis in patients with chronic HBV infection","volume":"29","author":"Huang","year":"2020","journal-title":"Discov Med"},{"key":"R14-20240826","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2020.11.003","article-title":"Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity","volume":"74","author":"Suslov","year":"2021","journal-title":"J Hepatol"},{"key":"R15-20240826","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/hep.31850","article-title":"HBV\/Pregenomic RNA increases the stemness and promotes the development of HBV-related HCC through reciprocal regulation with insulin-like growth factor 2 mRNA-binding protein 3","volume":"74","author":"Ding","year":"2021","journal-title":"Hepatology"},{"key":"R16-20240826","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1002\/hep.31616","article-title":"HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy","volume":"73","author":"Mak","year":"2021","journal-title":"Hepatology"},{"key":"R17-20240826","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00535-006-1856-4","article-title":"Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy","volume":"41","author":"Rokuhara","year":"2006","journal-title":"J Gastroenterol"},{"key":"R18-20240826","doi-asserted-by":"crossref","first-page":"975-","DOI":"10.1097\/QAD.0000000000003193","article-title":"Hepatitis B surface antigen and hepatitis B RNA changes in HIV\/HBV co-infected participants receiving HBV-active antiretroviral therapy for 144 weeks","volume":"36","author":"Hawkins","year":"2022","journal-title":"AIDS"},{"key":"R19-20240826","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cgh.2019.07.046","article-title":"Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy","volume":"18","author":"Fan","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R20-20240826","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy","volume":"72","author":"Carey","year":"2020","journal-title":"Hepatology"},{"key":"R21-20240826","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","author":"Seto","year":"2021","journal-title":"Gut"},{"key":"R22-20240826","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.30082","article-title":"Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection","volume":"68","author":"Butler","year":"2018","journal-title":"Hepatology"},{"key":"R23-20240826","doi-asserted-by":"crossref","first-page":"e11207","DOI":"10.7717\/peerj.11207","article-title":"Stability of hepatitis B virus pregenomic RNA in plasma specimens under various temperatures and storage conditions","volume":"9","author":"Rattanachaisit","year":"2021","journal-title":"PeerJ"},{"key":"R24-20240826","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"R25-20240826","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev drug discov"},{"key":"R26-20240826","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3390\/v13060951","article-title":"Novel biomarkers of Hepatitis B Virus and their use in chronic hepatitis B patient management","volume":"13","author":"Vachon","year":"2021","journal-title":"Viruses"},{"key":"R27-20240826","doi-asserted-by":"crossref","first-page":"e01056","DOI":"10.1128\/JCM.01056-18","article-title":"Standardization of nucleic acid tests: the approach of the World Health Organization","volume":"57","author":"Baylis","year":"2019","journal-title":"J Clin Microbiol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T11:08:26Z","timestamp":1724670506000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hc9.0000000000000099","relation":{},"ISSN":["2471-254X"],"issn-type":[{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"assertion":[{"value":"2022-11-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}